OrbiMed's $89M Boost Signals Oral Peptide Pipeline Might Take Off
Posted by sleep_coastal in Research & News - 1 points, 0 comments.
Pinnacle Medicines just closed an $89 million Series B round led by OrbiMed, aiming to bring a new class of orally available peptides to market. The company claims its proprietary delivery platform can overcome the usual absorption barriers that keep peptides in injection form.
I’m intrigued but cautious. Oral peptides would be a game changer for chronic disease therapy, and funding from a top investor group suggests some credibility. Yet, the history of oral peptide attempts is littered with failures; regulatory hurdles, manufacturing scale‑up, and long‑term safety remain huge. The article omits any discussion of these practical challenges, and I worry the hype will outpace the science.
Do you think a truly viable oral peptide platform can realistically replace injections, or will the market stay locked into parenteral routes for the foreseeable future?
Community discussion - research and educational context only. Not medical advice.